Bayer accelerates innovation for new cancer meds

by The Manila Times

Apr 29, 2022 6:28 am

FOUR major launches of innovative treatments Finerenone, Vericiguat, Larotrectinib and Darolutamide underscore Bayer's commitment to reducing the burden of cardiovascular diseases and cancer in the APAC region.

Despite seeing incredible progress over the past years, the overall burden of cancer is not decreasing, but increasing, with almost 20 million patients diagnosed with cancer worldwide in 2020. The global cancer burden is expected to be 28.4 million cases in 2040, a 47 percent rise from 2020.

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.

Related Articles

Natura &Co shows improved revenue trends, with strong performance by Natura in Brazil and signs of stability at Avon in the country

Helzberg Diamonds and Proximity join forces to elevate customer experience

UNESCO Intangible Cultural Heritage "Bunraku" on World Stage: Japan's National Theatre to Present Spectacular Fusion of Tradition and Anime in United States

AdvoLogix Announces: AI-Enhanced Matter Financial Management for Law Firms

NFP Acquires Orca Financial Group, a Specialist Financial Brokerage

rabbit r1, the Consumer AI-native Pocket Companion, Expands Availability Across the UK and European Union

Infortrend U.2 NVMe Storage Empowers Airport AI for Faster Passenger Processing